Compounds > 5-(2-bromovinyl)uracil
Page last updated: 2024-12-09

5-(2-bromovinyl)uracil

Description

5-(2-bromovinyl)uracil: RN given refers to (E)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID688297
CHEMBL ID68200
SCHEMBL ID65892
MeSH IDM0133833

Synonyms (25)

Synonym
brn 0744244
ccris 5284
5-bromovinyluracil
bv uracil
5-(2-bromovinyl)uracil
2,4(1h,3h)-pyrimidinedione, 5-(2-bromoethenyl)-, (e)-
(e)-5-(2-bromoethenyl)-2,4(1h,3h)-pyrimidinedione
69304-49-0
5-[(e)-2-bromovinyl]-1h-pyrimidine-2,4-dione
(e)-5-(2-bromovinyl)uracil
(e)-5-(2-bromovinyl)uracil, 97%
CHEMBL68200
5-[(e)-2-bromoethenyl]-1h-pyrimidine-2,4-dione
5-24-07-00368 (beilstein handbook reference)
AKOS015892588
SCHEMBL65892
e-5-(2-bromovinyl)uracil
BLXGZIDBSXVMLU-OWOJBTEDSA-N
(e)-5-(2-bromovinyl)pyrimidine-2,4(1h,3h)-dione
W-203539
brivudine impurity ((e)-5-(2-bromovinyl)uracil )
BCP24262
2,4(1h,3h)-pyrimidinedione, 5-[(1e)-2-bromoethenyl]-
AT24064
DTXSID801310909

Research Excerpts

Compound-Compound Interactions

ExcerptReferenceRelevance
"The fatal drug-drug interaction between sorivudine, an antiviral drug, and 5-fluorouracil (5-FU) has been shown to be caused by a mechanism-based inhibition."( Prediction of in vivo drug-drug interactions based on mechanism-based inhibition from in vitro data: inhibition of 5-fluorouracil metabolism by (E)-5-(2-Bromovinyl)uracil.
Ito, K; Kanamitsu, SI; Muro, K; Ogura, K; Okuda, H; Sugiyama, Y; Watabe, T, 2000)		0.51

Dosage Studied

ExcerptRelevanceReference
" All of these rats died within 10 days, whereas rats given SRV or tegafur alone under the same dosage conditions showed no appreciable change over 20 days compared with controls."( A possible mechanism of eighteen patient deaths caused by interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs.
Kato, A; Ogura, K; Okuda, H; Takubo, H; Watabe, T, 1998)		0.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (58)

Assay IDTitleYearJournalArticle
AID65543The compound was tested for its antiviral activity against HSV-2 (196) virus in E6SM cell culture1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID65555The concentration required to reduce the cytopathogenicity of HSV-1 (KOS) in E6SM cell culture by 50% in presence of 1 ug/mL of Urd1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID65547The compound was tested for its antiviral activity against vaccinia virus in E6SM cell culture1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID156854The concentration required to reduce the cytopathogenicity of HSV-1 (KOS) in PRK cell culture by 50% in presence of 100 ug/mL concentrations of 6-aminothymine1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID65686The concentration required to reduce the cytopathogenicity of HSV-1 (KOS) in E6SM cell culture by 50% in presence of 100 ug/ml concentrations of 6-aminothymine1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID65687The concentration required to reduce the cytopathogenicity of HSV-1 (KOS) in E6SM cell culture by 50% in presence of 20 ug/mL concentrations of 6-aminothymine1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID65554The concentration required to reduce the cytopathogenicity of HSV-1 (KOS) in E6SM cell culture by 50% in presence of 1 ug/mL dThd1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID156852The concentration required to reduce the cytopathogenicity of HSV-1 (KOS) in PRK cell culture 0 ug/mL specified concentrations of 6-aminothymine1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID156858The concentration required to reduce the cytopathogenicity of HSV-1 (KOS) in PRK cell culture by 50% in presence of 4 ug/mL concentrations of 6-aminothymine1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID65516The compound was tested for its antiviral activity against HSV-1 (KOS) virus in E1SM cell line1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID65676The concentration required to reduce the cytopathogenicity of HSV-1 (KOS) in E6SM cell culture by 50% in presence of 10 ug/mL concentrations of benzylacyclouridine1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID65679The concentration required to reduce the cytopathogenicity of HSV-1 (KOS) in E6SM cell culture by 50% in presence of 10 ug/mL of Urd and 50 ug/mL of 6-aminothymine,1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID65552The concentration required to reduce the cytopathogenicity of HSV-1 (KOS) in E6SM cell culture by 50% in presence of 0 ug/mL concentrations of 6-aminothymine1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID65540The compound was tested for its antiviral activity against HSV-1 (F) virus in E6SM cell culture1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID87291The concentration required to reduce the cytopathogenicity of HSV-1 (KOS) in HeLa cell culture by 50% in presence of 0 ug/mL concentrations of 6-aminothymine1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID63780The compound was tested for its antiviral activity against HSV-1 (KOS) virus in E6SM cell line1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID65546The compound was tested for its antiviral activity against TK-HSV-1 (B2006) virus in E6SM cell culture1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID65683The concentration required to reduce the cytopathogenicity of HSV-1 (KOS) in E6SM cell culture by 50% in presence of 100 ug/mL of Urd and 50 ug/mL of 6-aminothymine1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID65550The concentration required to reduce the cytopathogenicity of HSV-1 (KOS) in E6SM cell culture by 50% in absence of Urd1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID65688The concentration required to reduce the cytopathogenicity of HSV-1 (KOS) in E6SM cell culture by 50% in presence of 3 ug/mL dThd1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID65541The compound was tested for its antiviral activity against HSV-1 (KOS) virus in E6SM cell culture1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID65685The concentration required to reduce the cytopathogenicity of HSV-1 (KOS) in E6SM cell culture by 50% in presence of 100 ug/mL of dUrd and 50 ug/mL of 6-aminothymine1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID65551The concentration required to reduce the cytopathogenicity of HSV-1 (KOS) in E6SM cell culture by 50% in absence of dUrd1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID65693The concentration required to reduce the cytopathogenicity of HSV-1 (KOS) in E6SM cell culture by 50% in presence of 100 ug/mL dThd1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID216509The compound was tested for its antiviral activity against HSV-1 (KOS) virus in vero cell line1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID41208The compound was tested for its antiviral activity against HSV-1 (KOS) virus in BALB/3T3 cell line1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID65549The concentration required to reduce the cytopathogenicity of HSV-1 (KOS) in E6SM cell culture by 50% in absence of 0 ug/mL dThd1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID65556The concentration required to reduce the cytopathogenicity of HSV-1 (KOS) in E6SM cell culture by 50% in presence of 1 ug/mL of Urd and 50 ug/mL of 6-aminothymine1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID65544The compound was tested for its antiviral activity against HSV-2 (G) virus in E6SM cell culture1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID42109The compound was tested for its antiviral activity against HSV-1 (KOS) virus in BS-C-1A cell line1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID65680The concentration required to reduce the cytopathogenicity of HSV-1 (KOS) in E6SM cell culture by 50% in presence of 10 ug/mL of dUrd1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID87296The concentration required to reduce the cytopathogenicity of HSV-1 (KOS) in HeLa cell culture by 50% in presence of 4 ug/mL concentrations of 6-aminothymine1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID65689The concentration required to reduce the cytopathogenicity of HSV-1 (KOS) in E6SM cell culture by 50% in presence of 30 ug/mL dThd1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID65553The concentration required to reduce the cytopathogenicity of HSV-1 (KOS) in E6SM cell culture by 50% in presence of 0 ug/mL concentrations of benzylacyclouridine1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID65677The concentration required to reduce the cytopathogenicity of HSV-1 (KOS) in E6SM cell culture by 50% in presence of 10 ug/mL dThd1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID65548The compound was tested for its antiviral activity against vesicular stomatitis virus in E6SM cell culture1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID86514The compound was tested for its antiviral activity against HSV-1 (KOS) virus in HeLa cell line1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID65678The concentration required to reduce the cytopathogenicity of HSV-1 (KOS) in E6SM cell culture by 50% in presence of 10 ug/mL of Urd1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID209957The compound was tested for its antiviral activity against HSV-1 (KOS) virus in T-21 (LR) cell line1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID1657002Inactivation of bovine liver DHPDHase assessed as Kinact in presence of NADPH2020Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11
Acetylene Group, Friend or Foe in Medicinal Chemistry.
AID156856The concentration required to reduce the cytopathogenicity of HSV-1 (KOS) in PRK cell culture by 50% in presence of 20 ug/mL concentrations of 6-aminothymine1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID81898The compound was tested for its antiviral activity against HSV-1 (KOS) virus in HEp-2M cell line1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID103154The compound was tested for its antiviral activity against HSV-1 (KOS) virus M-21 (GM137) cell line1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID104933The compound was tested for its antiviral activity against HSV-1 (KOS) virus in MO cell line1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID65542The compound was tested for its antiviral activity against HSV-1 (McIntyre) virus in E6SM cell culture1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID65681The concentration required to reduce the cytopathogenicity of HSV-1 (KOS) in E6SM cell culture by 50% in presence of 10 ug/mL of dUrd and 50 ug/mL of 6-aminothymine1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID65675The concentration required to reduce the cytopathogenicity of HSV-1 (KOS) in E6SM cell culture by 50% in presence of 1 ug/mL of dUrd and 50 ug/mL of 6-aminothymine1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID65674The concentration required to reduce the cytopathogenicity of HSV-1 (KOS) in E6SM cell culture by 50% in presence of 1 ug/mL of dUrd1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID85246The compound was tested for its antiviral activity against HSV-1 (KOS) virus in HSF (VGS) cell line1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID65692The concentration required to reduce the cytopathogenicity of HSV-1 (KOS) in E6SM cell culture by 50% in presence of 50 ug/mL of 6-aminothymine1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID65682The concentration required to reduce the cytopathogenicity of HSV-1 (KOS) in E6SM cell culture by 50% in presence of 100 ug/mL of Urd1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID156542The compound was tested for its antiviral activity against HSV-1 (KOS) virus in PRK cell line1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID87294The concentration required to reduce the cytopathogenicity of HSV-1 (KOS) in HeLa cell culture by 50% in presence of 20 ug/mL concentrations of 6-aminothymine1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID65545The compound was tested for its antiviral activity against HSV-2 (Lyons) virus in E6SM cell culture1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID65691The concentration required to reduce the cytopathogenicity of HSV-1 (KOS) in E6SM cell culture by 50% in presence of 4 ug/mL concentrations of 6-aminothymine1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID65684The concentration required to reduce the cytopathogenicity of HSV-1 (KOS) in E6SM cell culture by 50% in presence of 100 ug/mL of dUrd1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID87292The concentration required to reduce the cytopathogenicity of HSV-1 (KOS) in HeLa cell culture by 50% in presence of 100 ug/mL concentrations of 6-aminothymine1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID65690The concentration required to reduce the cytopathogenicity of HSV-1 (KOS) in E6SM cell culture by 50% in presence of 300 ug/mL dThd1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (19)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (26.32)18.7374
1990's8 (42.11)18.2507
2000's5 (26.32)29.6817
2010's0 (0.00)24.3611
2020's1 (5.26)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.20

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.20 (24.57)
Research Supply Index3.18 (2.92)
Research Growth Index4.38 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.20)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (15.00%)5.53%
Reviews1 (5.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other16 (80.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
beta-alanine
[no description available]		210amino acid zwitterion;
beta-amino acid		agonist;
fundamental metabolite;
human metabolite;
inhibitor;
neurotransmitter
thymine
[no description available]		2.3720pyrimidine nucleobase;
pyrimidone		Escherichia coli metabolite;
human metabolite;
mouse metabolite
uracil
2,4-dihydroxypyrimidine: a urinary biomarker for bipolar disorder		9.2841pyrimidine nucleobase;
pyrimidone		allergen;
Daphnia magna metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
prodrug;
Saccharomyces cerevisiae metabolite
fluorouracil
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.. 5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.		5.9881nucleobase analogue;
organofluorine compound		antimetabolite;
antineoplastic agent;
environmental contaminant;
immunosuppressive agent;
radiosensitizing agent;
xenobiotic
tegafur
[no description available]		1.9910organohalogen compound;
pyrimidines
thymidine
[no description available]		1.9610pyrimidine 2'-deoxyribonucleosideEscherichia coli metabolite;
human metabolite;
metabolite;
mouse metabolite
floxuridine
Floxuridine: An antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection; when administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate. It has been used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.. floxuridine : A pyrimidine 2'-deoxyribonucleoside compound having 5-fluorouracil as the nucleobase; used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.		1.9810nucleoside analogue;
organofluorine compound;
pyrimidine 2'-deoxyribonucleoside		antimetabolite;
antineoplastic agent;
antiviral drug;
radiosensitizing agent
bromouracil
Bromouracil: 5-Bromo-2,4(1H,3H)-pyrimidinedione. Brominated derivative of uracil that acts as an antimetabolite, substituting for thymine in DNA. It is used mainly as an experimental mutagen, but its deoxyriboside (BROMODEOXYURIDINE) is used to treat neoplasms.. 5-bromouracil : A pyrimidine having keto groups at the 2- and 4-positions and a bromo group at the 5-position. Used mainly as an experimental mutagen.		7.69193nucleobase analogue;
pyrimidines		mutagen
trifluoromethyluracil
[no description available]		2.2510
uridine
[no description available]		6.9610uridinesdrug metabolite;
fundamental metabolite;
human metabolite
bromodeoxyuridine
Bromodeoxyuridine: A nucleoside that substitutes for thymidine in DNA and thus acts as an antimetabolite. It causes breaks in chromosomes and has been proposed as an antiviral and antineoplastic agent. It has been given orphan drug status for use in the treatment of primary brain tumors.		3.0750pyrimidine 2'-deoxyribonucleosideantimetabolite;
antineoplastic agent
cytarabine
[no description available]		1.9810beta-D-arabinoside;
monosaccharide derivative;
pyrimidine nucleoside		antimetabolite;
antineoplastic agent;
antiviral agent;
immunosuppressive agent
alpha-fluoro-beta-alanine
alpha-fluoro-beta-alanine: metabolite of HCFU & 5-fluorouracil; structure in first source		210organonitrogen compound;
organooxygen compound
deoxyuridine
[no description available]		2.3720pyrimidine 2'-deoxyribonucleosideEscherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
stavudine
Stavudine: A dideoxynucleoside analog that inhibits reverse transcriptase and has in vitro activity against HIV.. stavudine : A nucleoside analogue obtained by formal dehydration across positions 2 and 3 of thymidine. An inhibitor of HIV-1 reverse transcriptase		2.2510dihydrofuran;
nucleoside analogue;
organic molecular entity		antimetabolite;
antiviral agent;
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
selegiline
Selegiline: A selective, irreversible inhibitor of Type B monoamine oxidase that is used for the treatment of newly diagnosed patients with PARKINSON DISEASE, and for the treatment of depressive disorders. The compound without isomeric designation is Deprenyl.		2.2510selegiline;
terminal acetylenic compound		geroprotector
zidovudine
Zidovudine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia.. zidovudine : A pyrimidine 2',3'-dideoxyribonucleoside compound having a 3'-azido substituent and thymine as the nucleobase.		1.9810azide;
pyrimidine 2',3'-dideoxyribonucleoside		antimetabolite;
antiviral drug;
HIV-1 reverse transcriptase inhibitor
eniluracil
eniluracil: structure in first source; inactivates dihydropyrimidine dehydrogenase		2.2510pyrimidone
mifepristone
Mifepristone: A progestational and glucocorticoid hormone antagonist. Its inhibition of progesterone induces bleeding during the luteal phase and in early pregnancy by releasing endogenous prostaglandins from the endometrium or decidua. As a glucocorticoid receptor antagonist, the drug has been used to treat hypercortisolism in patients with nonpituitary CUSHING SYNDROME.		2.25103-oxo-Delta(4) steroid;
acetylenic compound;
tertiary amino compound		abortifacient;
contraceptive drug;
hormone antagonist;
synthetic oral contraceptive
zileuton
[no description available]		2.25101-benzothiophenes;
ureas		anti-asthmatic drug;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
ferroptosis inhibitor;
leukotriene antagonist;
non-steroidal anti-inflammatory drug
6-aminothymine
6-aminothymine: inhibits degradation of nucleosides (idoxuridine, thymidine) & pyrimidine bases		2.3720
edoxudin
[no description available]		1.9610pyrimidine 2'-deoxyribonucleoside
a-76745
fenleuton: LoFrin is tradename		2.2510
5-diazouracil
5-diazouracil: RN given refers to parent cpd; structure		2.4220
5-ethyluracil
5-ethyluracil: antagonist of dihydrouracil dehydrogenase (NADP)		2.3720
5-cyanouracil
[no description available]		2.2510
gefitinib
[no description available]		2.2510aromatic ether;
monochlorobenzenes;
monofluorobenzenes;
morpholines;
quinazolines;
secondary amino compound;
tertiary amino compound		antineoplastic agent;
epidermal growth factor receptor antagonist
erlotinib
[no description available]		2.2510aromatic ether;
quinazolines;
secondary amino compound;
terminal acetylenic compound		antineoplastic agent;
epidermal growth factor receptor antagonist;
protein kinase inhibitor
tv3326
[no description available]		2.2510indanes
brivudine
brivudine: anti-herpes agent		3.0750
5-(2-chloroethyl)-2'-deoxyuridine
5-(2-chloroethyl)-2'-deoxyuridine: inhibitor of herpes viruses; structure given in first source		1.9610pyrimidine 2'-deoxyribonucleoside
nadp
[no description available]		8.5120
2',3'-didehydro-3'-deoxy-4'-ethynylthymidine
2',3'-didehydro-3'-deoxy-4'-ethynylthymidine: a highly active anti-HIV agent; structure in first source		2.2510
sorivudine
[no description available]		11.5482organic molecular entity
bw b70c
BW B70C: arachidonic acid antagonist. BW B70C : A hydroxamic acid that is urea in which both the hydrogens attached to one of the nitrogens are replaced by a hydroxy and a (1E)-1-[3-(4-fluorophenoxy)phenyl]but-1-en-3-yl group. A selective inhibitor of arachidonate 5-lipoxygenase, it can be used for the treatment of asthma.		2.2510aromatic ether;
hydroxamic acid;
organofluorine compound;
ureas		EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor
enviradene
[no description available]		2.2510
5-(2-bromovinyl)uridine
5-(2-bromovinyl)uridine: structure given in first source		6.9610
epoxyfarnesyl diazoacetate
2'-deoxy-4'-C-ethynyl-2-fluoroadenosine: has anti-HIV activity; structure in first source		2.2510
pf9601n
[no description available]		2.2510
arabinofuranosyluracil
Arabinofuranosyluracil: A pyrimidine nucleoside formed in the body by the deamination of CYTARABINE.		6.5482
ConditionIndicatedRelationship StrengthStudiesTrials
Herpes Simplex Virus Infection
[description not available]		01.9610
Herpes Simplex
A group of acute infections caused by herpes simplex virus type 1 or type 2 that is characterized by the development of one or more small fluid-filled vesicles with a raised erythematous base on the skin or mucous membrane. It occurs as a primary infection or recurs due to a reactivation of a latent infection. (Dorland, 27th ed.)		01.9610
Dihydropyrimidine Dehydrogenase Deficiency
An autosomal recessive disorder affecting DIHYDROPYRIMIDINE DEHYDROGENASE and causing familial pyrimidinemia. It is characterized by thymine-uraciluria in homozygous deficient patients. Even a partial deficiency in the enzyme leaves individuals at risk for developing severe 5-FLUOROURACIL-associated toxicity.		02.0210
Bone Marrow Diseases
Diseases involving the BONE MARROW.		01.9910
Shingles
[description not available]		03.7821
Acute Disease
Disease having a short and relatively severe course.		03.3811
Herpes Zoster
An acute infectious, usually self-limited, disease believed to represent activation of latent varicella-zoster virus (HERPESVIRUS 3, HUMAN) in those who have been rendered partially immune after a previous attack of CHICKENPOX. It involves the SENSORY GANGLIA and their areas of innervation and is characterized by severe neuralgic pain along the distribution of the affected nerve and crops of clustered vesicles over the area. (From Dorland, 27th ed)		03.7821
Benign Neoplasms
[description not available]		01.9910
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		01.9910
Experimental Hepatoma
[description not available]		0210
Leukemia P388
An experimental lymphocytic leukemia originally induced in DBA/2 mice by painting with methylcholanthrene.		01.9610
Experimental Leukemia
[description not available]		01.9610
chemdatabank.com